Esphera SynBio Secures $2M for Nanomedicine Vaccine Development
Esphera SynBio, a Canadian synthetic biology company, has successfully closed a $2 million USD seed financing round. This significant investment is aimed at advancing the company’s pioneering work in developing nanomedicine vaccines for cancer and infectious diseases. The funding round was supported by key investors GKCC and FACIT, highlighting the potential and promise of Esphera’s innovative technology platform.
At the heart of Esphera’s approach is a breakthrough platform that utilizes proprietary transgenes to generate therapeutic exosomes in vivo. These engineered exosomes serve as nanomedicines, capable of delivering customized antigenic payloads to stimulate robust immune responses. This technology has the potential to enhance the efficacy of vaccines, offering personalized solutions to combat infectious diseases and cancer.
The financing will primarily be directed towards identifying an initial cancer vaccine clinical candidate and supporting general corporate purposes. Dr. Brian Lichty, co-founder and CEO of Esphera, emphasized the importance of this funding, stating that it enables the company to validate its vaccine platform and advance a potential best-in-class therapy for patients living with cancer. Lichty also highlighted the need to explore strategic partnerships to maximize the broad potential of their technology.
Esphera’s innovative platform is built on foundational intellectual property from the labs of Drs. Carolina Ilkow and John Bell at The Ottawa Hospital Research Institute and Dr. Lichty at McMaster University. The company operates research facilities in Hamilton, Ontario, and Ottawa, Ontario, and is focused on developing cancer immunotherapies, vaccines, and immunomodulatory therapies for a range of human diseases.
Dr. David O’Neill, Chair of the Board of Directors of Esphera and President of FACIT, underscored the transformative potential of Esphera’s approach. He noted that the company’s pioneering work places it at the forefront of a rapidly evolving field, with the team of entrepreneurial scientific leaders possessing the necessary experience to build a strong pipeline of innovative therapeutics.
The investment by FACIT, through its Compass Rose Oncology Fund, supports a collaboration based on homegrown intellectual property (IP), further emphasizing the potential of Esphera’s technology. The company’s lead product in development is a tumor immunotherapy that modifies tumor-derived exosomes, turning them into immunostimulatory personalized vaccines in situ.
Esphera’s technology platform allows for the production of modified exosomes through the expression of proprietary transgenes, which can be achieved both in vitro and in vivo. This versatility opens up various applications, including the generation of immunostimulatory, tumor-derived personalized vaccines, the enhancement of standard vaccines, and the delivery of specific RNAs to target cells.
With this significant funding, Esphera SynBio is poised to make significant strides in the development of nanomedicine vaccines, offering new hope for patients battling cancer and infectious diseases. The company’s innovative approach and commitment to advancing therapeutic solutions underscore its position as a leader in the field of synthetic biology.
See more funded startups in USA.